Journal of Endocrinological Investigation

, Volume 33, Issue 8, pp 554–558 | Cite as

Comparison between immunoradiometric and fluorimetric brain natriuretic peptide determination in patients with congestive heart failure

  • M. Feola
  • L. Valeri
  • E. Menditto
  • E. Nervo
  • F. Bianco
  • N. Aspromonte
  • R. Valle
  • G. Visconti
Original Articles


This study compared two different methods, namely the immunoradiometric (IRMA) and fluorimetric (FIA), in order to determine plasma brain natriuretic peptide (BNP) in congestive heart failure (CHF) patients. Methods: CHF in-patients underwent echocardiography and plasma BNP determination using both two methods. The echocardiograms analysed left ventricular end-systolic (LVESV) and end-diastolic (LVEDV) volumes and systolic dysfunction [left ventricular ejection fraction (LVEF) <50%]. Results: Seventy-three (71% males, age 67±9.6 yr) patients were enrolled, 31.5% affected by valvular heart disease. The mean LVEF was 39.8±14.1%; in 26 (35%) a hypertensive etiology emerged. The immunoradiometric assay (IRMA) BNP was found to be significantly lower than the FIA determination 116.5±149 pg/ml vs 267.3±285.6 pg/ml; p=0.0001) and the two methods were closely correlated (r=0.89; p=0.00001). Logistic regression demonstrated a significant correlation between BNP, LVEF, and LVESV/LVEDV (r=−0.45, p=0.0003; r=−0.48, p=0.00001; r=0.22 p=0.003; r=0.34 p=0.0001; r=0.13 p=0.02; r=0.28 p=0.001 IRMA and FIA, respectively). IRMA BNP and FIA BNP significantly increased according to the worsening functional class [from 34.3±60.2 pg/ml in NYHA (New York Heart Association) I to 555.5±273.1 pg/ml in NYHA IV; from 86.1 ±162.1 pg/ml in NYHA I to 1070±42.2 pg/ml in NYHA IV, respectively]. In severe systolic dysfunction (LVEF<30%), receiver operating characteristic analysis revealed a satisfactorily sensitivity and specificity using a cut-off point of 50.6 pg/ml with IRMA and 243 pg/ml with FIA. In mild systolic dysfunction (LVEF<50%), a good sensitivity and specificity using a cut-off point of 42 pg/ml with IRMA and 182 pg/ml with FIA emerged. Conclusions: In CHF patients both BNP methods correlated with NYHA class, LVEF, and ventricular volumes.


Brain natriuretic peptide congestive heart failure 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    de Lemos JA, McGuire DK, Drazner MH. B-Type natriuretic peptide in cardiovascular disease. Lancet 2003, 362: 316–22.PubMedCrossRefGoogle Scholar
  2. 2.
    Richards AM, Lainchbury JG, Nicholls MG, Cameron AV, Yandle TG. Dendroaspis natriuretic peptide: endogenous or dubious? Lancet 2002, 359: 5–6.Google Scholar
  3. 3.
    Mair J, Hammerer-Lercher A, Puschendorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 2001, 39: 571–88.PubMedCrossRefGoogle Scholar
  4. 4.
    Maisel A. B-Type natriuretic peptide levels: a potential novel “white count” for congestive heart failure. J Card Fail 2001, 7: 183–93.PubMedCrossRefGoogle Scholar
  5. 5.
    Clerico A. Pathofisiological and clinical relevance of circulating levels of cardiac natriuretic hormones: is their assay merely a marker of cardiac disease? Clin Chem Lab Med 2002, 40: 752–60.PubMedGoogle Scholar
  6. 6.
    Feola M, Aspromonte N, Canali C, et al. Prognostic value of plasma brain natriuretic peptide, urea nitrogen and creatinine in outpatients >70 years of age with heart failure. Am J Cardiol 2005, 96: 705–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Valle R, Aspromonte N, Feola M, et al. B-type natriuretic peptide can predict the medium-term risk in patients with acute heart failure and preserved systolic function. J Card Fail 2005, 11: 498–503.PubMedCrossRefGoogle Scholar
  8. 8.
    Vasan RS, Benjamin EJ, Larson MG, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction. JAMA 2002, 288: 1252–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Nakamura M, Endo H, Nasu M, Arakawa N, Segawa T, Hiramori K. Value of plasma B-Type natriuretic peptide measurement for heart disease screening in a Japanese population. Heart 2002, 87: 131–5.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, von Scheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001, 38: 1934–41.PubMedCrossRefGoogle Scholar
  11. 11.
    Lubien E, DeMaria A, Krishnaswamy P, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recording. Circulation 2002, 105: 595–601.PubMedCrossRefGoogle Scholar
  12. 12.
    Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnoea. J Am Coll Cardiol 2002, 39: 202–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Clerico A, Del Ry S, Giannessi D. Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptides) in clinical practice: the need for a new generation of immunoassay methods. Clin Chem 2000, 46: 1529–34.PubMedGoogle Scholar
  14. 14.
    Hammerer-Lercher A, Neubauer E, Muller S, Pachinger O, Puschendorf B, Mair J. Head-to-head comparison to N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosis left ventricular dysfunction. Clin Chim Acta 2001, 310: 193–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Prontera C, Emdin M, Zucchelli GC, Ripoli A, Passino C, Clerico A. Natriuretic peptides (NPs): Automated electrochemiluminescent immunoassay for N-terminal pro-BNP compared with IRMAs for ANP and BNP in heart failure patients and healthy individuals. Clin Chem 2003, 49: 1552–4.PubMedCrossRefGoogle Scholar
  16. 16.
    Sayama H, Nakamura Y, Saito N, Kinoshita M. Why is the concentration of plasma brain natriuretic peptide in elderly inpatients greater than normal? Coron Artery Dis 1999, 10: 537–40.PubMedCrossRefGoogle Scholar
  17. 17.
    Clerico A, Iervasi G, Del Chicca MG, et al. Analytical performance and clinical usefulness of a commercially available IRMA kit for the measurement of atrial natriuretic peptide in patients with heart failure. Clin Chem 1996, 42: 1627–33.PubMedGoogle Scholar
  18. 18.
    Clerico A, Iervasi G, Del Chicca MG, et al. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J Endocrinol Invest 1998, 21: 170–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Del Ry S, Clerico A, Giannessi D, et al. Measurement of brain natriuretic peptide in plasma samples and cardiac tissue extracts by means of and IRMA method. Scand J Clin Lab Invest 2000, 60: 81–90.PubMedCrossRefGoogle Scholar
  20. 20.
    Remme WJ, Swedberg K; Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001, 22: 1527–60.PubMedCrossRefGoogle Scholar
  21. 21.
    Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989, 2: 358–67.PubMedCrossRefGoogle Scholar
  22. 22.
    Fischer Y, Filzmaier K, Stiegler H, et al. Evaluation of a new, rapid test for quantitative determination of B-Type natriuretic peptide. Clin Chem 2001, 47: 591–4.PubMedGoogle Scholar
  23. 23.
    Baumgartner H. Neurohormones in valvular heart disease: what can they tell us? Eur Heart J 2008, 29: 290–2.PubMedCrossRefGoogle Scholar
  24. 24.
    Detaint D, Messika-Zeitoun D, Avierinos JF, et al. B-type natriuretic peptide in organic Mitral regurgitation. Determinants and impact on outcome. Circulation 2005, 111: 2391–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Kerr AJ, Raffel OC, Whalley GA, Zeng I, Stewart RA. Elevated B-type natriuretic peptide despite normal left ventricular function on rest and exercise stress echocardiography in mitral regurgitation. Eur Heart J 2008, 29: 363–70.PubMedCrossRefGoogle Scholar
  26. 26.
    Nielsen OW, McDonagh TA, Robb SD, Dargie HJ. Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic in screening for left ventricular systolic dysfunction in general population. J Am Coll Cardiol 2003, 41: 113–20.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2010

Authors and Affiliations

  • M. Feola
    • 1
  • L. Valeri
    • 2
  • E. Menditto
    • 1
  • E. Nervo
    • 1
  • F. Bianco
    • 3
  • N. Aspromonte
    • 4
  • R. Valle
    • 5
  • G. Visconti
    • 3
  1. 1.Cardiovascular Rehabilitation-Heart Failure UnitOspedale SS TrinitàFossanoItaly
  2. 2.Cardiology Division“SS. Annunziata” HospitalSavigliano
  3. 3.Laboratory Analysis“S. Croce-Carle” HospitalCuneo
  4. 4.Heart Failure Unit“S. Spirito” HospitalRome
  5. 5.Cardiology Division“Ospedale Civile”ChioggiaItaly

Personalised recommendations